JP2021512604A5 - - Google Patents

Info

Publication number
JP2021512604A5
JP2021512604A5 JP2020541938A JP2020541938A JP2021512604A5 JP 2021512604 A5 JP2021512604 A5 JP 2021512604A5 JP 2020541938 A JP2020541938 A JP 2020541938A JP 2020541938 A JP2020541938 A JP 2020541938A JP 2021512604 A5 JP2021512604 A5 JP 2021512604A5
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020541938A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512604A (ja
JP7539834B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/016430 external-priority patent/WO2019152895A1/en
Publication of JP2021512604A publication Critical patent/JP2021512604A/ja
Publication of JP2021512604A5 publication Critical patent/JP2021512604A5/ja
Priority to JP2024083146A priority Critical patent/JP2024119840A/ja
Application granted granted Critical
Publication of JP7539834B2 publication Critical patent/JP7539834B2/ja
Priority to JP2025245658A priority patent/JP2026048820A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020541938A 2018-02-01 2019-02-01 ガレクチン-3に対する抗体及びその使用方法 Active JP7539834B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024083146A JP2024119840A (ja) 2018-02-01 2024-05-22 ガレクチン-3に対する抗体及びその使用方法
JP2025245658A JP2026048820A (ja) 2018-02-01 2025-12-11 ガレクチン-3に対する抗体及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862625166P 2018-02-01 2018-02-01
US62/625,166 2018-02-01
PCT/US2019/016430 WO2019152895A1 (en) 2018-02-01 2019-02-01 Antibodies to galectin-3 and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024083146A Division JP2024119840A (ja) 2018-02-01 2024-05-22 ガレクチン-3に対する抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2021512604A JP2021512604A (ja) 2021-05-20
JP2021512604A5 true JP2021512604A5 (enExample) 2022-02-24
JP7539834B2 JP7539834B2 (ja) 2024-08-26

Family

ID=67479885

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020541938A Active JP7539834B2 (ja) 2018-02-01 2019-02-01 ガレクチン-3に対する抗体及びその使用方法
JP2024083146A Pending JP2024119840A (ja) 2018-02-01 2024-05-22 ガレクチン-3に対する抗体及びその使用方法
JP2025245658A Pending JP2026048820A (ja) 2018-02-01 2025-12-11 ガレクチン-3に対する抗体及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024083146A Pending JP2024119840A (ja) 2018-02-01 2024-05-22 ガレクチン-3に対する抗体及びその使用方法
JP2025245658A Pending JP2026048820A (ja) 2018-02-01 2025-12-11 ガレクチン-3に対する抗体及びその使用方法

Country Status (6)

Country Link
US (2) US12180285B2 (enExample)
EP (1) EP3746123A4 (enExample)
JP (3) JP7539834B2 (enExample)
AU (1) AU2019215202B2 (enExample)
CA (1) CA3089988A1 (enExample)
WO (1) WO2019152895A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
JP7835441B2 (ja) * 2019-12-06 2026-03-25 トゥルーバインディング,インコーポレイテッド Gal3とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法
BR112022013892A2 (pt) * 2020-01-13 2022-10-04 Truebinding Inc Anticorpos anti-gal3 e métodos de uso
EP4157338A4 (en) * 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CN112062832B (zh) * 2020-09-24 2021-08-03 河南赛诺特生物技术有限公司 Galectin-3抗原表位肽、抗原、抗体、杂交瘤细胞株及试剂盒
WO2022125482A1 (en) * 2020-12-08 2022-06-16 Memorial Sloan Kettering Cancer Center Antibodies to galectin-3 and methods of use thereof
CN115746134A (zh) * 2021-10-15 2023-03-07 深圳市睿盟创新生物科技有限公司 半乳糖凝集素-3的免疫测定

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US825A (en) 1838-07-09 Bail way cooking-stove
US5851A (en) 1848-10-17 Machinery for doubling and twisting tarn
US198A (en) 1837-05-15 Mode of constructing boats for canals
US5569A (en) 1848-05-16 Corn-sheller
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2374910A1 (fr) 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US4824659A (en) 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU610083B2 (en) 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
JPS6412935A (en) 1987-07-02 1989-01-17 Mitsubishi Electric Corp Constant-speed travel device for vehicle
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
DE69230613T2 (de) 1991-07-02 2000-12-28 Inhale Inc Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
AU4829593A (en) 1992-09-23 1994-04-12 Fisons Plc Inhalation device
SK51695A3 (en) 1992-10-19 1995-11-08 Dura Pharma Inc Dry powder medicament inhaler
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
US5849695A (en) 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
WO1994016970A1 (en) 1993-01-19 1994-08-04 Glaxo Group Limited Device
EP0804561B1 (en) 1993-02-12 2009-12-30 The Board Of Trustees Of The Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
GB9526100D0 (en) 1995-12-20 1996-02-21 Intersurgical Ltd Nebulizer
EP0938907B1 (en) 1996-01-03 2001-12-05 Glaxo Group Limited Inhalation device
US6027947A (en) 1996-08-20 2000-02-22 Ramtron International Corporation Partially or completely encapsulated top electrode of a ferroelectric capacitor
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2230848T3 (es) 1998-04-28 2005-05-01 Smithkline Beecham Corporation Anticuerpos monoclonales con inmunogenicidad reducida.
ES2331051T3 (es) 1999-11-29 2009-12-21 Bac Ip B.V. Inmovilizacion de moleculas de union de antigenos de un dominio.
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US20050032673A1 (en) * 2002-06-10 2005-02-10 John Constance M. Sustained release N-terminally truncated galectin-3 and antibodies to galectin-3 carbohydrate ligands for use in treating disease
DE602004014485D1 (de) 2003-04-07 2008-07-31 Prospect Therapeutics Inc Zusammensetzung und anwendungen von galectin-antagonisten
WO2005035575A2 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
AU2009298458B2 (en) 2008-09-30 2015-10-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
ES2984483T3 (es) 2010-03-31 2024-10-29 Ablexis Llc Ingeniería genética de ratones para la producción de anticuerpos quiméricos
EP3323830B1 (en) 2010-06-19 2023-08-23 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
US8765797B2 (en) * 2010-06-21 2014-07-01 Board Of Regents, The University Of Texas System TG2 inhibitors and uses thereof
WO2014089267A1 (en) * 2012-12-05 2014-06-12 Eleven Biotherapeutics, Inc. Galectin-3 fusion proteins
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
SG11201707538XA (en) 2015-03-17 2017-10-30 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
CN107383192B (zh) 2017-07-19 2018-08-24 深圳市倍诺博生物科技有限公司 半乳糖凝集素-3检测试剂盒
CN111201030B (zh) * 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
EP3466975A1 (en) * 2017-10-05 2019-04-10 Laboratoire Français du Fractionnement et des Biotechnologies A specific binding molecule directed against galectin-3 protein

Similar Documents

Publication Publication Date Title
JP2021512604A5 (enExample)
JP7461950B2 (ja) Cd3抗体およびその医薬用途
TWI805121B (zh) 抗SIRPα抗體及其用途
JP2019519492A5 (enExample)
CN112969476B (zh) 多特异性蛋白分子
JP2019524693A5 (enExample)
JP2019536470A5 (enExample)
JP2024501581A5 (enExample)
KR20180089497A (ko) Fc 수용체-유사 5를 표적화하는 항체 및 사용 방법
JP2018504890A (ja) Gタンパク質共役受容体を標的化する抗体および使用の方法
RU2019121086A (ru) Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1)
CN114641504A (zh) 抗b7h4抗体及其双抗和应用
WO2024175093A1 (en) Antibodies, antigen-binding fragments and methods of use
JP2020502233A5 (enExample)
JP2022513050A5 (enExample)
KR20240164815A (ko) 항-tigit/항-pvrig 이중특이적 항체, 이의 약제학적 조성물 및 이의 용도
US20240309099A1 (en) Bispecific tetravalent antibody targeting egfr and her3
WO2023186063A1 (zh) 抗pvrig抗体、其药物组合物及用途
JP2021529524A5 (enExample)
RU2025109828A (ru) Антитела против b7h3 и способы их применения
TW202432593A (zh) 抗體、其抗原結合片段及其藥物用途
WO2025206223A1 (ja) 抗ヒトクローディン18.2抗体及びその使用
WO2025117872A1 (en) Bispecific antibody-like protein and methods of making and using thereof
IL321672A (en) Anti-pdl1/vegf antibodies and methods of use
IL321674A (en) Anti-cd47 antibodies and methods of use